Agreement Advances Development of Tronox's Critical Minerals Processing Capabilities Across Australia, the United States, and Japan

STAMFORD, Conn., Sept. 29, 2026 /PRNewswire/ -- Tronox Holdings plc (NYSE: TROX) ("Tronox"), the world's leading integrated manufacturer of titanium dioxide ("TiO2") pigment, today announced the signing of a cooperation and investment agreement with JX Advanced Metals Corporation (TYO: 5016) ("JXAM") to advance the development of its rare earth and critical minerals business to support growing demand for these minerals in semiconductor, advanced electronics, robotics, automotive, defense, and other high-technology applications.

Under the signed agreement, Tronox and JXAM (together "the Companies") will fund on a 50/50 basis approximately $32 million to support a definitive feasibility study for Tronox's previously announced proposed rare earth cracking and leaching facility ("Cracking Plant") in Australia and a pre-feasibility study for a proposed rare earth oxide refinery ("Refinery") in the United States and development of a US-based pilot facility capable of producing initial quantities of high-purity rare earth oxides. Tronox and JXAM anticipate that the joint investment in feasibility work for the Cracking Plant and Refinery will demonstrate the technical, economic, environmental, and commercial viability of establishing an integrated rare earth processing and refining platform. The agreement also contemplates joint development of other critical minerals and materials from Tronox's mineral resources, including niobium (Nb), scandium (Sc), zirconium (Zr), and hafnium (Hf), all of which are critical to the economic and national security of the United States and Japan.

The joint cooperation and investment agreement with JXAM represents a key milestone for Tronox in the development of its rare earth supply chain that could enable significant value creation. The agreement reflects the shared commitment of Tronox and JXAM to establish new capabilities across the critical mineral value chain while supporting the economic security and industrial competitiveness objectives of the United States, Australia, and Japan, including the Pax Silica Initiative.

The Companies plan to locate the Cracking Plant in the Rockingham Industrial Zone in Western Australia, approximately three kilometers south of Tronox's Kwinana TiO2 pigment plant, enabling shared services and other resources that can be leveraged due to Tronox's extensive footprint and infrastructure in Australia, where it employs more than 1,200 people at its existing operations. The Companies currently expect to locate the Refinery on Tronox-owned land adjacent to its existing Hamilton, Mississippi TiO2 pigment facility, where it employs more than 400 people. The site has access to abundant and low-cost power, existing utilities, reagents, and substantial infrastructure that Tronox expects would provide meaningfully lower refining costs versus a typical new entrant.

Together, as currently contemplated, the two sites would aim to produce up to 10,000 tonnes per annum of total rare earth oxides. Tronox's mines have an attractive mineralogy mix of light and heavy rare earth refinery feedstock, including neodymium (Nd) and praseodymium (Pr), dysprosium (Dy) and terbium (Tb), samarium (Sm), gadolinium (Gd), and yttrium (Y).

Tronox's Chief Executive Officer John D. Romano commented, "This strategic agreement represents an important milestone in Tronox's efforts to leverage our unique mineral sands resources and hydrometallurgical and chemical processing expertise to participate in the rapidly growing critical minerals value chain. By combining Tronox's mining resources and reserves and project development capabilities with JXAM's advanced refining and materials expertise, we are creating a pathway toward a secure, reliable, and globally competitive source of high-purity rare earth oxides and other critical minerals."

Hayashi Yoichi, President and Chief Executive Officer of JXAM, added, "Rare earths are essential to the advanced materials at the core of our growth strategy, and diversifying and strengthening their supply chain is an important strategic priority for JX Advanced Metals. Through this joint study, we will bring together Tronox's mineral resources and mineral separation capabilities with our technologies and expertise in nonferrous metals smelting and recycling to evaluate the potential of a rare earth processing business in Australia, the United States, and other locations. Working in close partnership and leveraging our complementary strengths, we aim to strengthen the supply chain supporting our advanced materials businesses and create new business opportunities that contribute to the sustainable growth of both companies."

The cooperation and investment agreement contemplates that if the Cracking Plant and Refinery engineering studies demonstrate technical and commercial viability, Tronox and JXAM will explore the formation of a joint venture to fund, build, and operate the assets. The Companies have engaged with several government-backed financing institutions, including the US Export-Import Bank, Export Finance Australia, relevant Japanese financial institutions and organizations, and other government-supported and commercial lenders regarding potential funding, which could represent a significant portion of the project's capital structure.

Mr. Romano concluded, "The strategic importance of a diversified and secure rare earth supply chain has never been greater. As the proposed projects would contribute to strengthening supply chains in the United States, Japan and Australia, we also hope to receive support from the relevant authorities and other stakeholders in each country."

About Tronox

Tronox Holdings plc is one of the world's leading producers of high-quality titanium products, including titanium dioxide pigment, specialty-grade titanium dioxide products and high-purity titanium chemicals, and zircon. We mine titanium-bearing mineral sands and operate upgrading facilities that produce high-grade titanium feedstock materials, pig iron and other minerals, including the rare earth-bearing mineral, monazite. With approximately 5,700 employees across six continents, our rich diversity, unmatched vertical integration model, and unparalleled operational and technical expertise across the value chain, position Tronox as the preeminent titanium dioxide producer in the world. For more information about how our products add brightness and durability to paints, plastics, paper and other everyday products, visit tronox.com.

About JXAM

JX Advanced Metals Corporation is a global player in advanced materials related to copper, minor metals, and other nonferrous metals. JXAM operates its businesses based on an integrated supply chain that extends from securing resources to recycling. It operates under five business lines: Thin Film Materials, Tantalum and Niobium, Functional Materials, Metal & Recycling, and Mineral Resources. JXAM's head office is located in Tokyo, Japan. The company employs 10,413 on a consolidated basis, or 3,267 on a non-consolidated basis, as of March 31, 2025.

Cautionary Statement about Forward-Looking Statements 

Statements in this release that are not historical are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements, which are subject to known and unknown risks, uncertainties and assumptions about us, may include projections of our future financial performance, our operating rates, anticipated completion of extensions and upgrades to our mining operations, anticipated trends in our business and industry, including trade defense measures in specific jurisdictions and their timing and effectiveness, market penetration and growth rates, anticipated costs, competitive landscape, benefits and timing of capital projects including planned mining expansions, the Company's anticipated capital allocation strategy including future capital expenditures, the benefits and timing of the Company's cost improvement and other cost saving, inventory reduction and asset rationalization plans, our sustainability goals, commitments and programs, our rare earths and critical minerals strategy, including any expectation that the cooperation and investment agreement with JX will demonstrate the technical, economic, environmental, and commercial viability of establishing an integrated rare earth processing and refining platform, any expectation that we will be successful in forming a joint venture with JX to, among other things, fund, build, and operate the proposed Cracking Plant and Refinery, any expectation that the Company will be successful in constructing and/or operating the proposed Cracking Plant and Refinery, any expectation that the Company will be successful in arranging all required financing and/or developing a financeable structure with respect to its rare earths and critical minerals initiatives, and any expectation that the Company will be successful in developing a rare earth supply chain in Australia and/or the United States. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance, actual costs, benefits and timing of capital projects, or the cost improvement plan and other cost saving, inventory reduction and asset rationalization plans, or achievements to differ materially from the results, level of activity, performance, anticipated costs, benefits and timing of capital projects, or the cost improvement plan and other cost saving, inventory reduction and asset rationalization plans, or achievements expressed or implied by the forward-looking statements.

Three new Peanutters will travel the country in the 26-foot-long NUTmobile beginning in June 2027

- The PLANTERS® NUTmobile is hiring three Peanutters to hit the salty streets in June 2027.

- Applications are open through Nov. 1. College graduates can apply for this once in a lifetime opportunity with a resume and creative video.

- Peanutters travel the country in the NUTmobile, create social media content, work with media and execute events, while earning a salary and benefits.

AUSTIN, Minn., Sept. 29, 2026 /PRNewswire/ -- The PLANTERS® NUTmobile is hitting the road again, and the PLANTERS® brand is seeking three adventurous Peanutters to join the ride beginning in June 2027.

The NUTmobile is a 26-foot-long peanut on wheels and the center of a year-round experiential marketing program. Peanutters drive the NUTmobile, create social media content, plan and execute hundreds of events and stops, connect with local and national media and surprise and delight brand fans across the country.

One Shell of an Opportunity

The PLANTERS® brand is seeking college graduates who are engaging storytellers, confident communicators and savvy social content creators with a willingness to jump into nutty situations. Prospective Peanutters must submit a resume and short video showing what they would bring to the role. Creativity and humor are highly encouraged.

Travel enthusiasts with an appetite for adventure and salty snacks are encouraged to apply at BeAPeanutter.com through Nov. 1, 2026.

"The Peanutters have an incredible opportunity to take the brand on the road while gaining experiences they'll remember long after the job is over," said Patrick Horbas, director of marketing for the PLANTERS® brand. "They get to travel, meet people from all over, experience some unique events and make connections along the way. It's a chance to step outside their everyday routine, have some fun and be part of something that's unlike any other job."

For Those Who Go Nuts for a Road Trip

Trade in a desk job for a year in the driver's seat. Peanutters crisscross the country bringing the PLANTERS® brand to life at sporting events, festivals, college campuses, community events and more. Last year's class of Peanutters traveled to 41 states and logged over 30,000 miles on their journey, all while receiving an annual salary, full-time benefits, generous meal and travel stipends and real-world marketing and PR experience.

When the road trip rolls to its final stop, Peanutters are encouraged to apply for full-time roles at Hormel Foods to continue their careers.

In a Nutshell

This isn't your typical entry-level role — it's a once-in-a-lifetime adventure featuring a 26-foot-long peanut on wheels. From unexpected encounters to unforgettable road trip moments, no two days on the road are the same. Along the way, Peanutters gain valuable real-world experience in a marketing, public relations, content creation and communication while making memories and friendships that can last a lifetime.

To Be or Nut to Be

Ready to throw your name in the top hat? Apply now at BeAPeanutter.com and get ready to go nuts. 

About the PLANTERS® Brand

Founded in 1906 in Wilkes-Barre, Pa., the Planters® brand has been the ultimate snacking solution for consumers for over a century with a vast portfolio of peanuts, snackable nut mixes, seeds and so much more. No matter what you're craving — salted, unsalted, dry roasted, honey roasted, whole nuts, half nuts, peanuts, mixed nuts — Planters® products have you covered. The Planters® brand, which has been owned by Hormel Foods Corporation (NYSE: HRL) since 2021, is also home to the beloved Mr. Peanut® character, who is currently touring the salty streets of America in his world-famous NUTmobile. Fans of the Planters® brand can request the world's largest peanut on wheels by submitting a request at plantersnutmobile.com. For more information on all Planters® products, visit planters.com.

About Hormel Foods

Hormel Foods Corporation, based in Austin, Minnesota, is a global branded food company with over $12 billion in annual revenue. Its brands include PLANTERS®, SKIPPY®, SPAM®, HORMEL® NATURAL CHOICE®, APPLEGATE®, WHOLLY®, HORMEL® BLACK LABEL®, COLUMBUS®, JENNIE-O® and more than 30 other beloved brands. The Company is a member of the S&P 500 Index and the S&P 500 Dividend Aristocrats, was named one of the best companies to work for by U.S. News & World Report and one of America's most responsible companies by Newsweek, was recognized by TIME magazine as one of the World's Best Companies and has received numerous other awards and accolades for its corporate responsibility and community service efforts. For more information, visit hormelfoods.com.

Frequently Asked Questions

How do I apply to become a 2027 PLANTERS® Peanutter?

Applicants can apply at BeAPeanutter.com through Nov. 1, 2026. Applicants must submit a resume and a short, creative video showing what they would bring to the role.

What does a Peanutter do?

Peanutters travel across the country in the 26-foot-long NUTmobile, creating social media content, working with local and national media, planning and executing events and connecting with PLANTERS® brand fans along the way.

Where do Peanutters travel?

Peanutters travel throughout the United States, making stops at sporting events, festivals, college campuses, community events and other destinations. The 2026 class traveled to 41 states and met more than 160,000 people.

Is the Peanutter position a paid job?

Yes. The Peanutter position is a paid, full-time role. Peanutters receive an annual salary, full-time benefits and generous meal and travel stipends.

When does the 2027 Peanutter job begin?

The 2027 Peanutter class will begin traveling in the NUTmobile in June 2027.

Who is eligible to become a Peanutter?

The PLANTERS® brand is seeking college graduates who are engaging storytellers, confident communicators and savvy social content creators. Applicants should also be comfortable traveling extensively and representing the PLANTERS® brand at events and in local and national media.

Contact:

Hormel Foods

[email protected]

Catherine Maddrey

[email protected]

SOURCE Hormel Foods Corporation

Share this article

Proactive, life-stage-aware care could improve outcomes, reduce downstream costs and may support a modeled health span increase of up to 20 years

NEW YORK, Sept. 29, 2026 /PRNewswire/ --

Key takeaways

- Prevention could expand health span: Under a prevention and improved disease-management scenario, women's health span could potentially increase by up to 20 years in the long-run model.

- Proactive care presents a potential half-trillion-dollar modeled demand opportunity: Deloitte analysis estimates that shifting healthcare from reactive to proactive, life-stage-aware care may create $527 billion in additional potential spending on U.S. women's health in 2030 as compared to the modeled baseline trajectory.

- Clinical needs and market demand are converging: Among 22 care areas, four of them — brain health, pelvic health, cardiovascular care, and musculoskeletal/autoimmune conditions — illustrate where unmet needs and market demand may converge.

Why this matters

Deloitte's Future of Health framework suggests that moving from reactive treatment toward more proactive, individualized care may improve patient health and help healthcare resources work more effectively. In this analysis, Deloitte's actuarial Future of Health modeling approach — which uses five years of medical and pharmacy claims data from nearly 60 million lives — was adapted to compare baseline spending trajectory with a scenario that assumes prevention, earlier detection and improved management.

The resulting report, "How a $527 billion growth opportunity in women's health can improve health outcomes," explores how earlier, life-stage-aware interventions may improve women's health outcomes while supporting sustainable market growth.

Deloitte's analysis indicates that risk does not appear distributed evenly across women's life stages, and some of the greatest clinical and financial gains may come from intervening earlier. Reproductive years and midlife represent important windows where earlier recognition, prevention and improved management may help reduce disease progression and avoid more severe chronic disease later in life.

Key quotes

"By increasing focus on proactive, life-stage-aware health interventions to address unmet needs, the health industry may add up to 20 years of healthy life span for women. This transition supports the potential for improved clinical outcomes across a lifetime, greater economic vitality across the broader healthcare ecosystem, and enhanced quality of life for patients."

— Kulleni Gebreyes, MD, principal, vice chair and U.S. life sciences and healthcare industry leader, Deloitte

"The modeled $527 billion shift represents a demand-generated signal for investors and medtech, pharma and digital health innovators to consider scaling platforms such as continuous monitoring and early diagnostic technologies. By deploying these lower-friction tools to diagnose earlier, the industry can drive sustainable investments while fundamentally improving how women and their care teams navigate their lifelong health journeys."

— Jen Radin, MPH, senior life sciences and healthcare principal, Deloitte

Four clinical focus areas illustrating where unmet needs and market demand may converge

Women's health is often framed around reproductive care, but this report organizes the market into three overlapping pillars: conditions that disproportionately affect women, conditions that present differently in women, and conditions linked to female biology across life stages. The report highlights four categories that fall into one or more of these pillars where unmet patient needs and emerging market technologies appear to be converging to create modeled additional potential spending:

- Brain and neurological conditions ($44 billion market): Biological and hormonal factors are associated with some related symptoms and disease activity. Improving neurological care at scale may depend on translating insights about sex-specific biology and life-stage factors into earlier, more accessible interventions such as using blood-based biomarkers.

- Pelvic, reproductive and hormonal health ($21 billion market): Conditions such as polyendocrine metabolic ovarian syndrome (PMOS) and cervical cancer are seeing shifts toward consumer-driven diagnostics — such as at-home self-collection devices — and research into metabolic treatments like GLP-1 receptor agonists.

- Cardiovascular health and stroke ($49 billion market): Hormonal changes, pregnancy history, and other risk factors can potentially play a role in women's cardiovascular care needs. Innovation is moving toward sex-specific diagnostics, including AI-enabled cardiovascular screening integrated into routine mammography workflows, and continuous wearable monitoring tools.

- Musculoskeletal, autoimmune and inflammatory health ($56 billion market): Disorders within this category often disproportionately affect women. Shifts underway include AI-enabled software used to screen routine hip and pelvis X-rays for early signs of low bone density, while the pharmaceutical pipeline expands to include disease-modifying therapies for joint degeneration.

Shifting care closer to the individual can create new options for ecosystem stakeholders

There are practical considerations for stakeholders seeking to design solutions around women's evolving biological needs across life stages:

- Medtech and pharmaceutical companies can embed sex-specific biological insights into early-stage product design and strengthen real-world evidence.

- Health plans and employers can consider benefit designs to facilitate early preventive screenings and reduce out-of-pocket costs, helping avoid costly downstream acute care.

- Investors can direct capital toward scalable, repeatable platforms that advance sex-specific diagnostics and treatments to help address unmet demand through innovation and investment.

- Consumer health organizations can design accessible, daily-use services that support women through life-stage transitions, such as pregnancy and menopause.

Methodology

This analysis adapts Deloitte's actuarial Future of Health modeling approach, which uses five years of medical and pharmacy claims data from nearly 60 million lives. Medical and pharmacy claims from 2019 and 2023 were classified into four categories and 22 disease states then scaled to represent the broader U.S. population. The modeled 2030 projections compare a baseline trajectory, which assumes current trends continue with an intervention scenario focused on targeted investments in prevention, earlier detection, and improved disease management.

About Deloitte

Deloitte provides industry-leading audit, consulting, tax and advisory services to many of the world's most admired brands, including nearly 90% of the Fortune 500® and more than 9,000 U.S.-based private companies. At Deloitte, we strive to live our purpose of making an impact that matters for our people, clients, and communities. We bring together distinct talents, technologies, disciplines, and an ecosystem of alliances to help tackle today's most complex business challenges and drive long-term progress. Deloitte is proud to be part of the largest global professional services network serving our clients in the markets that are most important to them. Bringing more than 180 years of service, our network of member firms spans more than 150 countries and territories. Learn how Deloitte's approximately 470,000 people worldwide connect for impact at www.deloitte.com.

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee ("DTTL"), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as "Deloitte Global") does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the "Deloitte" name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms.

SOURCE Deloitte

Share this article

New $2M research investment aims to solve a major unmet need in pulmonary medicine: accurately assessing indeterminate lung nodules and accelerating life-saving diagnoses

WASHINGTON, Sept. 29, 2026 /PRNewswire/ -- LUNGevity Foundation, the nation's leading lung cancer–focused nonprofit organization, today announced its support of two innovative and ambitious research projects designed to fundamentally change how clinicians evaluate indeterminate pulmonary nodules (IPNs), small spots on chest CT scans that may be an early sign of lung cancer.

Each year, more than 1.5 million Americans receive CT scan results showing an IPN. Yet existing non-invasive diagnostic approaches often fall short, leaving patients and providers unable to determine whether a nodule is benign or malignant. As a result, many individuals undergo unnecessary invasive procedures, experience prolonged diagnostic delays, or live with profound uncertainty and anxiety during this critical window of early detection.

Through targeted investment and strategic collaboration, LUNGevity is working with Rising Tide Foundation for Clinical Cancer Research (RTFCCR) to close this diagnostic gap and accelerate the development of more precise, non-invasive tools that can identify cancer earlier, reduce harm, and improve outcomes for patients worldwide.

While both of these studies represent bold, patient-centered innovation needed to transform how we detect lung cancer, each offers a unique approach for how health care teams assess a person's risk for the disease.

"We know the most effective health care tools must work for both the patient and the clinic. By advancing two strong choices in assessing lung cancer risk, we are opening the door for more people to have access to this information. One project aims to combine radiomics and liquid biopsy to determine a person's lung cancer risk, while the other project builds on advanced AI algorithms to offer a personalized risk assessment," said Upal Basu Roy, PhD, MPH, executive director of LUNGevity Research. "We are proud to partner with Rising Tide Foundation to support the development of tools that can finally bring clarity to millions of patients facing uncertainty after a CT scan."

The two projects are supported through the 2026 RTFCCR/LUNGevity Early Detection Award, a partnership dedicated to accelerating high-impact early detection research that can be rapidly translated into clinical practice.

Award Recipients

Project: Validation of an Integrated Radiomic and Cell-Free DNA Methylome Biomarker for Risk Stratification of Indeterminate Pulmonary Nodules

Awardee: Steven Dubinett, MD

Institution: University of California, Los Angeles

Amount: $1 million (over 3 years)

This three-year study aims to develop a powerful diagnostic tool that integrates advanced CT imaging analysis with a blood-based test to predict the likelihood that an indeterminate pulmonary nodule is cancerous. The research team will validate the approach in a cohort of 500 patients across UCLA and Veterans Affairs hospitals, with the ultimate goal of providing clinicians with a reliable, non-invasive method to assess cancer risk in patients with IPNs.

Project: The RESOLVE Study – Risk Estimation Using Sybil for Lung Nodules

Awardee: Lecia Sequist, MD, MPH

Institution: Massachusetts General Hospital / Harvard Medical School

Amount: $1 million (over 3 years)

This three-year clinical trial will evaluate Sybil, an open-source artificial intelligence model capable of estimating lung cancer risk directly from CT scans, without reliance on human annotation of the images. The study will enroll 340 adults ages 35–75 with low-risk pulmonary nodules, testing the real-world performance of AI-driven risk assessment in a diverse clinical population.

If successful, these studies could:

- Significantly reduce unnecessary biopsies and surgeries

- Expand access to early detection through non-invasive approaches, particularly for women without common risk factors for lung cancer, who now represent a growing proportion of lung cancer diagnoses

- Enable faster identification of high-risk patients who require prompt follow-up or early intervention

"Each of these projects is led by a globally recognized expert in lung cancer research and developed with contribution of expert patient partners. They reflect the kind of visionary science that can redefine patient care," said Zoraide Granchi, PhD, senior scientific program manager of the Rising Tide Foundation for Clinical Cancer Research. "We are proud to once again partner with LUNGevity to accelerate patient-focused solutions that bring hope, clarity, and progress to patients and families around the world."

LUNGevity Foundation is grateful to Upstage Lung Cancer for their continued partnership in supporting early detection research.

About Rising Tide for Clinical Cancer Research

Founded in 2010 and headquartered in Schaffhausen, Switzerland, the Rising Tide Foundation for Clinical Cancer Research (RTFCCR) is a charitable, non‑profit organization dedicated to advancing patient‑centered clinical cancer research. Its mission is to support innovative clinical trials that lead to less toxic therapies, earlier detection, and improved quality of life for cancer patients, with a strong focus on projects that address real patient needs and deliver meaningful impact on survival and well‑being.

Learn more at: https://www.risingtide-foundation.org

About LUNGevity Foundation

LUNGevity, the nation's leading lung cancer organization, is transforming what it means to be diagnosed and live with lung cancer. LUNGevity seeks to make an immediate impact on quality of life and survivorship for everyone touched by the disease, while promoting health equity by addressing disparities throughout the care continuum.

- Through research, we use an innovative and holistic approach to finding lung cancer earlier when it is most treatable; advance research into new treatments so people may live longer and better; and ensure a diverse, vital pipeline of investigators for the future of the lung cancer field.

- Through advocacy, we foster groundbreaking collaborations to ensure all people have access to screening, biomarker testing, and treatment breakthroughs.

- Through community, we educate, support, and connect people affected by lung cancer so that they can get the best healthcare and live longer and better lives.

Comprehensive resources include a medically vetted and patient-centric website, Patient Gateways for specific types of lung cancer, a toll-free HELPLine for personalized support, international survivor conferences, and tools to find a clinical trial. All these programs are designed to help us achieve our vision: a world where no one dies of lung cancer. LUNGevity Foundation is proud to be a four-star Charity Navigator organization.

Please visit www.LUNGevity.org to learn more.

SOURCE LUNGevity Foundation

Share this article

Envision Energy Named to Fortune's 2026 Change the World List for Advancing AI and Green Energy Convergence

SHANGHAI, Sept. 29, 2026 /PRNewswire/ -- Envision Energy, a global leader in green technology, has been named to Fortune's 2026 Change the World list, marking the company's third appearance on the list. Envision was recognized for Mission Gobi and its first flagship project, the Envision Galaxy Campus, which explored a new model for integrating energy and computing infrastructure in the AI era.

Fortune's 2026 Change the World list brings together 50 companies exploring innovative ways to address global social and environmental challenges. From Alphabet and Anthropic in AI to CATL in renewable energy, the honorees represent a range of industries and approaches. Envision's recognition highlights Mission Gobi's exploration of the convergence of AI and green energy, and how abundant renewable resources can support the next generation of AI infrastructure.

As AI drives rapid growth in computing demand, energy is becoming a fundamental foundation of the AI era. Rather than simply adding new demand to existing power systems, Envision is exploring how computing can be brought closer to abundant renewable resources, with energy and computing infrastructure developed together.

Launched in June 2026, Mission Gobi aims to develop 5GW of green AI computing capacity in desert and arid regions around the world by 2030, leveraging abundant wind and solar resources. Its first flagship project, the Envision Galaxy Campus in Ulanqab, Inner Mongolia, is designed to scale beyond 2GW of computing capacity and support up to one million chips simultaneously, according to Fortune. Powered primarily by renewable energy, the project explores how regions once seen as energy-constrained or remote can become new sources of energy abundance and new foundations for AI infrastructure.

"AI takes intelligence further; green energy can take civilization further still." said Lei Zhang, Founder and CEO of Envision, "Envision will continue to explore their convergence: moving energy from scarcity toward abundance, from limits toward affordability. Let the sun and wind become new gifts to civilization, turning lands once seen as barren into new spaces of energy abundance. Where energy and intelligence reinforce one another, new possibilities for civilisation can emerge."

Envision's three appearances on Fortune's Change the World list reflect the evolution of its innovation journey: from renewable energy innovation in 2021, to large-scale net-zero industrial parks and full-stack green hydrogen technologies in 2024, and now to the convergence of AI and energy. Ultimately, it is a journey to expand the boundaries of what energy can make possible for humanity.

Share this article

Huawei Launches Intelligent RAIL 2.0 to Accelerate Global Railway Intelligence Upgrade

BERLIN, Sept. 29, 2026 /PRNewswire/ -- At InnoTrans 2026, the world's largest rail transport exhibition held from September 22 to 25, Huawei unveiled Intelligent RAIL 2.0, a new generation of solutions designed to provide multi-scenario intelligent solutions for the global rail industry. The launch event brought together industry organizations such as UIC (International Union of Railways) and UITP (International Association of Public Transport), along with global customers and ecosystem partners, to explore the future of the industry.

Jean-Michel Evanghelou, Director Digital Systems & Innovation, and Financial Control & Project Operations from UIC, stated that FRMCS will be the first step for rail operators to build a solid digital foundation. He added that AI applications will continue to deepen and integrate into the core systems of the rail industry, making the standardization of AI applications increasingly important.

Mohamed Mezghani, Secretary-General of UITP, and Lidia Signor, Head of Multimodal Transport at UITP, also attended the event. Lidia Signor delivered a speech titled "Global Metro AI Intelligence and Automation," highlighting that UITP, in collaboration with the China Association of Metro (CAMET), has released a research report titled "AI-Driven Smart Rail Transport." The report showcases how AI solutions have been deployed in various systems, including metro construction, operation, and maintenance, improving the operational efficiency and safety levels of rail transport systems.

In his keynote speech, Raymond Zuo, President of Huawei's Smart Rail BU, pointed out that as human society enters the era of intelligence, more and more stakeholders are exploring ways to integrate digital and intelligent technologies into their core business processes to address traditional pain points. Looking at the trends, infrastructure will evolve from GSM-R to FRMCS, equipment maintenance will shift toward condition-based and predictive maintenance, freight will develop toward an end-to-end service-oriented logistics model that includes multimodal transport, passenger services will move toward seamless travel experiences, and engineering construction will increasingly adopt digital and intelligent technologies to enhance safety and operational efficiency.

Based on its innovative practices with leading global customers, Huawei has creatively proposed the "intelligent RAIL" innovation strategy. This strategy leverages digital and intelligent technologies to continuously enhance railway safety (Reliable), efficiency (Automated), integrated services (Integrated-serviced), and long-term evolution (Long-termed). Additionally, by defining key technologies across generations, Huawei has launched the new generation of intelligent RAIL 2.0 at this conference, which includes 20 scenario-based solutions. These solutions focus on three core areas—construction, passenger and freight transportation, and facility and equipment maintenance—addressing long-standing industry challenges and pain points. These scenario-based solutions are jointly developed by Huawei and its partners, with Huawei focusing on communication and digital platforms, and partners specializing in industry applications, to provide modular and combinable solutions tailored to the needs of industry customers based on specific business scenarios.

To date, Huawei has served more than 50 major railway customers worldwide and over 300 urban rail lines, covering more than 180,000 kilometers of track. Huawei is not only a leading global provider of ICT products but also a trusted partner for digital transformation in the intelligent era. Looking ahead, Huawei will continue to implement its "platform + ecosystem" strategy, working together with global customers and partners to deepen industry collaboration, gain insights into the evolving technological trends in the rail industry, and promote the deep integration of cutting-edge technologies with rail scenarios. By continuously iterating and innovating its solutions, Huawei aims to empower global rail transportation to move toward a safer, more efficient, and greener intelligent future.

SOURCE Huawei

Share this article

Bybit Expands TradFi Perp Options with Tesla, QQQ, SOXL and More, Launches Trading Challenge with Up to 70,000 USDT in Prizes

DUBAI, UAE, Sept. 29, 2026 /PRNewswire/ -- Bybit, the New Financial Platform trusted by more than 80 million users worldwide, expanded its Perp Options offerings with six new underlying assets and announced the Wall Street Blue-Chip Options Challenge, opening up two rewards tracks for participants while they explore opportunities across the globe from Invesco QQQ to SK Hynix.

Bybit Perp Options, the industry's first options contracts built on Bybit's TradFi Perpetuals, officially went live on September 17, 2026 with SpaceX and NVIDIA as the first available underlyings. Starting now, Tesla, Invesco QQQ (Nasdaq 100 ETF), Direxion Semiconductor Bull 3X ETF (SOXL), Micron Technology, SK Hynix, and Sandisk join the lineup, bringing the total to eight tickers this month.

Also starting today, the Bybit Wall Street Blue-Chip Options Challenge is open to all users until October 27, 2026, offering two ways for traders to win bonus rewards:

- New-User First Trade: A 5,000 USDT prize pool offering 5 USDT to each of the first 1,000 qualifying users who place their first valid TradFi Perp Options trade during the event.

- Volume Challenge: A prize pool of up to 65,000 USDT, unlocked in tiers based on collective trading volume across all participants and distributed to the top 50 traders by individual volume.

New users looking to trade global markets with Perp Options stand to claim from both prize pools.

Bybit Perp Options gives traders round-the-clock access to global equity options directly from their USDT-funded Bybit accounts, without requiring a separate broker or options-approved brokerage account. Contracts trade 24/7 with European-style settlement and no early assignment, settle in cash via USDT, and support fractional lot sizes, naked options, combo strategies, and full portfolio and cross-margin support through Bybit's single Unified Trading Account.

How It Works

- Open Bybit and navigate to TradFi, then select the Perp Options tab.

- Choose a ticker, such as TSLA, NVDA, or SPCX.

- Select an expiry date and strike price, then buy or sell calls or puts.

- At expiry, positions settle automatically in USDT.

For terms and conditions, full eligibility criteria, reward tiers, and distribution details, user may visit: Wall Street Blue-Chip Options Challenge: Share 70,000 USDT in rewards

About Bybit

Bybit is The New Financial Platform.

We believe every person should have access to every financial opportunity on earth. That's why we're building the first intelligent platform that connects anyone, anywhere to the world's finance.

Trusted by more than 80 million users worldwide, Bybit brings together investing, trading, payments, and wealth-building in a single secure and intelligent ecosystem. Through the combination of AI-powered technology, deep global liquidity, robust security, and transparent operations, Bybit makes global finance more accessible, efficient, and empowering for everyone.

Built for everyone. Powered by intelligence. Open to the world.

Learn more at Bybit.com.

For more details about Bybit, please visit Bybit Press

For media inquiries, please contact: [email protected]

For updates, please follow: Bybit's Communities and Social Media

Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube

SOURCE Bybit

Share this article

2026 IMS Oral Presentation: Innovent Announces Updated Phase 1 Clinical Data of Trispecific Antibody IBI3003 (GPRC5D/BCMA/CD3) in Patients with Relapsed or Refractory Multiple Myeloma

SAN FRANCISCO and SUZHOU, China, Sept. 29, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of innovative medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, announced updated Phase 1 clinical data for IBI3003, a novel trispecific antibody targeting GPRC5D, BCMA, and CD3, in patients with relapsed or refractory multiple myeloma (R/R MM) in an oral presentation at the 23rd International Myeloma Society (IMS) Annual Meeting 2026. Based on the results of the Phase 1 dose optimization study, the recommended Phase 2 dose (RP2D) of IBI3003 was determined to be 360 μg/kg. At the RP2D, IBI3003 demonstrated rapid, deep, and durable response signals, particularly in heavily pretreated, high-risk patients with extramedullary disease.

IBI3003 is a novel trispecific antibody targeting G protein-coupled receptor C5D (GPRC5D), B-cell maturation antigen (BCMA), and CD3. Its dual-targeting design against BCMA and GPRC5D is intended to overcome tumor escape caused by the loss or downregulation of a single tumor antigen. In preclinical mouse models, IBI3003 demonstrated superior in vivo anti-tumor activity compared with marketed benchmark bispecific antibodies targeting GPRC5D/CD3 or BCMA/CD3, with particularly prominent tumor-killing activity in in vitro cell models with low expression of BCMA and GPRC5D. Currently, Innovent is conducting Phase 1/2 clinical trials of IBI3003 in China, Australia, and the United States (NCT06083207 and NCT07336472) to evaluate its safety, tolerability, and preliminary efficacy in patients with R/R MM. In parallel, Innovent has advanced the Phase 3 TriadicMM-1 study (NCT07623798) in China for IBI3003 in patients with R/R MM who have received 1 to 4 prior lines of therapy. In addition, the Phase II study of IBI3003 combined with CD38 monoclonal antibody for frontline MM is also ongoing (NCT07764861).

The updated data were from the Phase 1 clinical study NCT06083207, which enrolled eligible patients with R/R MM who had failed at least two prior lines of therapy, including at least one proteasome inhibitor (PI), one immunomodulatory drug (IMiD), and one anti-CD38-based therapy, and who had relapsed or were refractory to their last anti-myeloma regimen. Patients with prior BCMA- and/or GPRC5D-targeted therapy were also eligible for enrollment. IBI3003 was administered subcutaneously once weekly (QW). Patients who received continuous treatment for ≥6 months and achieved a partial response (PR) or better for ≥2 months could switch to once-every-two-weeks (Q2W) dosing for maintenance. To reduce the risk of cytokine release syndrome (CRS), 1 to 3 priming doses were incorporated into the study design.

A total of 102 patients were enrolled in this phase of the study in China and Australia, with doses ranging from 0.1 μg/kg to 800 μg/kg. The median patient age was 62 years (range: 40-88), 37.1% of patients were classified as high risk according to mSMART criteria, and 53.9% had ≥1 site of extramedullary disease (EMD). The median number of prior lines of therapy was 4 (range: 2-12). All patients had received at least three classes of therapy, including a PI, an IMiD, and an anti-CD38 antibody. Among them, 55.9% had received at least five classes of therapy, including at least two PIs, two IMiDs, and one anti-CD38 antibody; 33.3% had previously received anti-BCMA and/or anti-GPRC5D therapies; and 88.2% were refractory to their last treatment. As of the data cutoff date of June 30, 2026, the median follow-up duration was 6.65 months (range: 0.8-15.2).

Rapid, Deep, and Durable Responses Observed with IBI3003 at 360 μg/kg

Based on an integrated analysis of the efficacy, safety, and pharmacokinetic/pharmacodynamic (PK/PD) data from dose optimization cohorts receiving IBI3003 at 120, 360, and 540 μg/kg in the Phase 1 study, the RP2D was determined to be 360 μg/kg.

A total of 26 patients received IBI3003 at 360 μg/kg, with a median follow-up duration of 7.57 months. mPFS was not reached yet.

- The overall response rate (ORR) was 84.6%, including 11 cases of stringent complete response (sCR), 4 cases of very good partial response (VGPR), and 7 cases of partial response (PR). The ORR was 94.7% among 19 patients who had received 2 to 4 prior lines of therapy, 87.5% among 8 patients with non-bone-related EMD, and 92.3% among 13 patients without EMD.

- The median time to first response was 0.99 months (range: 0.9-8.3 months), the median time to first response of ≥VGPR was 1.87 months (range: 0.9-4.6 months), and the median time to first response of ≥CR was 2.79 months (range: 0.9-9.2 months).

- Among patients who achieved CR or better as assessed by central laboratory next-generation sequencing (NGS) testing, the minimal residual disease (MRD) negativity rate was 100% (n=8). Three patients achieved MRD negativity after receiving only one treatment cycle.

Manageable Safety Profile of IBI3003 in Patients with R/R MM

- Hematologic toxicities were the most common Grade ≥3 treatment-related adverse events (TRAEs), occurring primarily during the dose-escalation phase and being manageable and reversible.

- The incidences of CRS and immune effector cell-associated neurotoxicity syndrome (ICANS) were 52% and 3.9%, respectively. All events were Grade 1-2 and resolved with treatment. Prophylactic use of tocilizumab may reduce the risk of CRS.

- The incidence of infections was 42.2%, with Grade ≥3 infections reported in 26.5% of patients.

- For GPRC5D target-related TEAEs involving the oral cavity, skin, and nails, no Grade ≥3 oral TEAEs were observed. Most skin and nail TEAEs were Grade 1-2, with only two patients experiencing Grade 3 rash.

Potent and Sustained Pharmacodynamic Responses Observed with IBI3003 in Patients with R/R MM

- Biomarker analyses showed a significant and sustained decline in serum soluble BCMA (sBCMA) levels across the IBI3003 120 μg/kg, 360 μg/kg, and 540 μg/kg dose groups.

- Deep and durable reductions in sBCMA levels were observed across all dose groups. After three treatment cycles, the median reduction from baseline in sBCMA levels was 98.38% in the IBI3003 360 μg/kg group.

IBI3003 continued to demonstrate encouraging and durable responses, together with a manageable safety profile, in heavily pretreated patients with R/R MM. These efficacy and safety data support further evaluation of the clinical value of IBI3003 in the ongoing Phase 3 clinical study.

Professor Peng Liu of Zhongshan Hospital Affiliated to Fudan University stated, "Patients with R/R MM have a poor prognosis after failing treatments including PIs, IMiDs, and anti-CD38-based therapies, with an ORR of only 29.8%, a median progression-free survival of 4.6 months, and a median overall survival of 12.4 months[1]. Although bispecific antibodies are reshaping the treatment landscape of R/R MM, trispecific antibodies targeting two antigens simultaneously may help overcome treatment resistance caused by intra-tumor and inter-tumor heterogeneity, as well as treatment-induced antigen escape. A substantial unmet clinical need remains in R/R MM, particularly among heavily pretreated and high-risk patients.

The dual-target coverage of BCMA and GPRC5D by IBI3003 addresses antigen expression heterogeneity and treatment resistance associated with single-target therapies, thereby reducing tumor escape. Its optimized CD3 affinity enables precise T-cell activation and tumor killing while improving safety. In the Phase 1 results presented at this meeting, IBI3003 demonstrated a manageable safety profile and impressive efficacy at the 360 μg/kg dose, with an ORR of 84.6%. Significant efficacy was also observed in patients with EMD or other high-risk features, fully demonstrating the potential of IBI3003 to overcome treatment resistance. The ORR reached 94.7% among patients who had received 2 to 4 prior lines of therapy. We look forward to the results of the ongoing Phase 3 clinical study of IBI3003."

About IBI3003 (Anti-GPRC5D/BCMA/CD3 Trispecific Antibody)

IBI3003 was developed using Innovent's proprietary Sanbody® platform. It is a novel trispecific antibody targeting G protein-coupled receptor C5D (GPRC5D), B-cell maturation antigen (BCMA), and CD3. The molecule was designed to overcome tumor escape caused by the loss or downregulation of a single tumor antigen. In preclinical mouse models, IBI3003 demonstrated superior in vivo anti-tumor activity compared with marketed benchmark bispecific antibodies. It also demonstrated particularly prominent tumor-killing activity in in vitro cell models with low expression of BCMA and GPRC5D.

Phase 1/2 clinical trials of IBI3003 (NCT06083207 and NCT07336472) are being conducted concurrently in China, Australia, and the United States to evaluate its safety, tolerability, and efficacy in patients with R/R MM. In China, IBI3003 has advanced into a pivotal registrational clinical stage. TriadicMM-1 (NCT07623798) is a multicenter, randomized, open-label Phase 3 study designed to compare the efficacy and safety of IBI3003 with investigator's choice of therapy in patients with R/R MM who have received 1 to 4 prior lines of therapy. The primary endpoint is progression-free survival (PFS) assessed by an independent review committee (IRC). In addition, the Phase II study of IBI3003 combined with CD38 monoclonal antibody for frontline MM is also ongoing (NCT07764861).

About Innovent

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals.

Reactive Technologies launches Nyquist licensing programme to accelerate grid innovation through technology partnerships

Nyquist gives utilities, technology providers and equipment manufacturers access to selected technologies from Reactive Technologies' patented Edge-to-Cloud AI foundation, helping partners reduce development complexity and bring advanced grid solutions to market faster through flexible licensing, integration and co-development.

LONDON, Sept. 29, 2026 /PRNewswire/ -- Reactive Technologies today announced the launch of Nyquist, a new technology partnership programme that opens access to selected technologies and expertise developed through the company's work with power system operators and utilities worldwide.

Nyquist enables partners to build advanced measurement and intelligence capabilities directly into their own products and applications, avoiding the need to develop complex sensing, signal-processing and analytical technologies from the ground up.

The rise of inverter-based resources, battery storage, data centres and other power-electronic loads is making power systems increasingly dynamic, making higher-resolution measurement, faster processing and more sophisticated analysis increasingly essential to maintaining grid stability and reliability.

Through Nyquist, partners can access and integrate technologies from Reactive Technologies' patented Edge-to-Cloud AI foundation, spanning high-fidelity measurement and waveform capture, precise time-synchronisation, digital signal processing, edge AI, connectivity, data infrastructure and grid analytics. These technologies are already successfully deployed with leading utilities worldwide, helping them understand their power system like never before and confidently respond to the rapid growth of inverter-based resources and large-load connections. The programme extends the reach of these technologies through partnership, accelerating their adoption and impact across the industry.

"We are continually approached by organisations looking to collaborate with us, and now Nyquist offers a structured way to do that " said Marc Borrett, CEO of Reactive Technologies. "Nyquist allows our strategic partners to build on the core technologies and expertise we have developed over many years, while retaining the flexibility to create solutions that fit their own customers, markets and applications."

To learn more about Nyquist, please visit:

https://reactive-technologies.com/nyquist/

About Reactive Technologies

Reactive Technologies is a global Grid-Enhancing Technologies (GETs) company addressing the challenges of energy transition, electrification and accelerating load growth.

With the proven GridVerix® platform, Reactive Technologies provides real-time, data-driven insights into grid stability and reliability, underpinned by grounded measurement and delivered through a data-as-a-service model. This enables grid operators, utilities and asset owners worldwide to plan and operate with greater visibility, efficiency and resilience as the grid continues to evolve.

For more information, visit reactive-technologies.com.

SOURCE Reactive Technologies

Share this article

Pearson Acquires Workera, a Pioneer in AI-Native Enterprise Assessment and Skills Verification

Pearson strengthens enterprise offering with adaptive assessment and skills intelligence to meet growing demand for workforce transformation in the era of AI

LONDON, Sept. 29, 2026 /PRNewswire/ -- Pearson (FTSE: PSON.L), the world's lifelong learning company, today announced it has agreed to acquire Workera, the AI-native skills intelligence platform used by leading enterprises to verify what their workforce can actually do.

Workera combines agentic AI, psychometrics and adaptive assessment to measure demonstrated proficiency through role-specific scenarios and simulations. Its proven technology and top tier talent will accelerate Pearson's ability to help enterprises build the workforce they need for AI-driven transformation, reflecting Pearson's continued investment in enterprise skilling.

Workera's technology gives business leaders:

- A live baseline of workforce capability, including AI fluency

- Targeted development, sending each employee to the specific learning that closes their gaps

- Verified outcomes that show whether skills actually improved, giving leaders defensible ROI on AI and learning investments

- Better talent decisions across hiring, internal mobility, redeployment and strategic workforce planning

Vishaal Gupta, President, Enterprise Learning & Skills at Pearson, said: "In the era of AI, an organization's ability to assess and develop skills will be key. Workera has pioneered a new approach to continuously measuring and validating workforce capabilities, giving organizations an accurate understanding of the skills they have today and what they will need in the future. Combining Workera's talented workforce and technology, with Pearson's expertise in learning and assessment, strengthens our ability to help enterprises close skills gaps faster and build more agile and capable workforces."

Kian Katanforoosh, founder and CEO, Workera, said: "The future will require all of us to develop new skills and learn faster than ever. We built Workera to harness AI so people can discover what they're capable of, organizations can recognize talent they might otherwise overlook, and learning can lead to progress you can actually see. Pearson has helped people learn and grow around the world for generations. Together, we'll bring Workera's AI and Pearson's deep expertise in learning and assessment to a shared ambition: building the gold standard for workforce readiness and helping people achieve more than they thought possible."

Workera serves blue-chip enterprises, including leaders such as ServiceNow, Accenture, and the United States Space Force. Upon completion, Workera will become part of Pearson's Enterprise Learning & Skills business unit, and Workera co-founder and CEO Kian Katanforoosh will join its leadership team.

Workera was founded in 2019 and is headquartered in Palo Alto, California, USA. The company serves enterprise and government customers and has a team of approximately 60 people.

Completion of the acquisition is expected to occur in H2 2026 subject to regular closing conditions, including any required regulatory filings or approvals.

About Pearson

At Pearson, our purpose is simple: to help people realise the life they imagine through learning. We believe that every learning opportunity is a chance for a personal breakthrough. That's why our c.18,000 Pearson employees are committed to creating vibrant and enriching learning experiences designed for real-life impact. We are the world's lifelong learning company, serving customers in nearly 200 countries with digital learning and assessments experiences, verified skills, and credentials. For us, learning isn't just what we do. It's who we are. Visit us at plc.pearson.com.

Share this article